Cargando…
Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
BACKGROUND: Rebamipide with mucin secretagogue activity was recently approved for the treatment of dry eye. The efficacy and safety in the treatment of rebamipide were shown in two pivotal clinical trials. It was the aim of this study to evaluate the effect of 2 % rebamipide ophthalmic suspension in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456696/ https://www.ncbi.nlm.nih.gov/pubmed/26048396 http://dx.doi.org/10.1186/s12886-015-0040-0 |
_version_ | 1782374865008852992 |
---|---|
author | Ueda, Kaori Matsumiya, Wataru Otsuka, Keiko Maeda, Yoshifumi Nagai, Takayuki Nakamura, Makoto |
author_facet | Ueda, Kaori Matsumiya, Wataru Otsuka, Keiko Maeda, Yoshifumi Nagai, Takayuki Nakamura, Makoto |
author_sort | Ueda, Kaori |
collection | PubMed |
description | BACKGROUND: Rebamipide with mucin secretagogue activity was recently approved for the treatment of dry eye. The efficacy and safety in the treatment of rebamipide were shown in two pivotal clinical trials. It was the aim of this study to evaluate the effect of 2 % rebamipide ophthalmic suspension in patients with dry eye and analyze relevant factors for favorable effects of rebamipide in clinical practice. METHODS: This was a retrospective cohort study of 48 eyes from 24 patients with dry eye treated with 2 % rebamipide ophthalmic suspension. Dry eye-related symptom score, tear film break-up time (TBUT), fluorescein ocular surface staining score (FOS) and the Schirmer test were used to collect the data from patients at baseline, and at 2, 4, 8, and 12 week visits. To determine the relevant factors, multiple regression analyses were then performed. RESULTS: Mean dry eye-related symptom score showed a significant improvement from the baseline (14.5 points) at 2, 4, 8 and 12 weeks (9.80, 7.04, 7.04 and 7.83 points, corrected P value <0.001, respectively). Median FOS showed a significant improvement from the baseline (3.0 points) at 2, 4, 8 and 12 weeks (2.0, 2.0, 1.0 and 1.0 points, corrected P value <0.001, respectively). TBUT and Schirmer test values were not significantly improved after the treatment. For ocular symptoms, three parameters (foreign body sensation, dry eye sensation and ocular discomfort) showed significant improvements at all visits. The multiple regression analyses showed that the fluorescein conjunctiva staining score was significantly correlated with the changes of dry eye-related symptom score at 12 weeks (P value = 0.017) and dry eye-related symptom score was significantly correlated with independent variables for the changes of FOS at 12 weeks (P value = 0.0097). CONCLUSIONS: Two percent rebamipide ophthalmic suspension was an effective therapy for dry eye patients. Moreover the fluorescein conjunctiva staining score and dry eye-related symptom score might be good relevant factors for favorable effects of rebamipide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12886-015-0040-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4456696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44566962015-06-06 Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye Ueda, Kaori Matsumiya, Wataru Otsuka, Keiko Maeda, Yoshifumi Nagai, Takayuki Nakamura, Makoto BMC Ophthalmol Research Article BACKGROUND: Rebamipide with mucin secretagogue activity was recently approved for the treatment of dry eye. The efficacy and safety in the treatment of rebamipide were shown in two pivotal clinical trials. It was the aim of this study to evaluate the effect of 2 % rebamipide ophthalmic suspension in patients with dry eye and analyze relevant factors for favorable effects of rebamipide in clinical practice. METHODS: This was a retrospective cohort study of 48 eyes from 24 patients with dry eye treated with 2 % rebamipide ophthalmic suspension. Dry eye-related symptom score, tear film break-up time (TBUT), fluorescein ocular surface staining score (FOS) and the Schirmer test were used to collect the data from patients at baseline, and at 2, 4, 8, and 12 week visits. To determine the relevant factors, multiple regression analyses were then performed. RESULTS: Mean dry eye-related symptom score showed a significant improvement from the baseline (14.5 points) at 2, 4, 8 and 12 weeks (9.80, 7.04, 7.04 and 7.83 points, corrected P value <0.001, respectively). Median FOS showed a significant improvement from the baseline (3.0 points) at 2, 4, 8 and 12 weeks (2.0, 2.0, 1.0 and 1.0 points, corrected P value <0.001, respectively). TBUT and Schirmer test values were not significantly improved after the treatment. For ocular symptoms, three parameters (foreign body sensation, dry eye sensation and ocular discomfort) showed significant improvements at all visits. The multiple regression analyses showed that the fluorescein conjunctiva staining score was significantly correlated with the changes of dry eye-related symptom score at 12 weeks (P value = 0.017) and dry eye-related symptom score was significantly correlated with independent variables for the changes of FOS at 12 weeks (P value = 0.0097). CONCLUSIONS: Two percent rebamipide ophthalmic suspension was an effective therapy for dry eye patients. Moreover the fluorescein conjunctiva staining score and dry eye-related symptom score might be good relevant factors for favorable effects of rebamipide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12886-015-0040-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-06 /pmc/articles/PMC4456696/ /pubmed/26048396 http://dx.doi.org/10.1186/s12886-015-0040-0 Text en © Ueda et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ueda, Kaori Matsumiya, Wataru Otsuka, Keiko Maeda, Yoshifumi Nagai, Takayuki Nakamura, Makoto Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title | Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title_full | Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title_fullStr | Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title_full_unstemmed | Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title_short | Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
title_sort | effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456696/ https://www.ncbi.nlm.nih.gov/pubmed/26048396 http://dx.doi.org/10.1186/s12886-015-0040-0 |
work_keys_str_mv | AT uedakaori effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye AT matsumiyawataru effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye AT otsukakeiko effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye AT maedayoshifumi effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye AT nagaitakayuki effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye AT nakamuramakoto effectivenessandrelevantfactorsof2rebamipideophthalmicsuspensiontreatmentindryeye |